JPH02501192A - 可溶性ｔ４蛋白を製造するためのｄｎａ配列、組換ｄｎａ分子および方法 - Google Patents

可溶性ｔ４蛋白を製造するためのｄｎａ配列、組換ｄｎａ分子および方法

Info

Publication number
JPH02501192A
JPH02501192A JP63507739A JP50773988A JPH02501192A JP H02501192 A JPH02501192 A JP H02501192A JP 63507739 A JP63507739 A JP 63507739A JP 50773988 A JP50773988 A JP 50773988A JP H02501192 A JPH02501192 A JP H02501192A
Authority
JP
Japan
Prior art keywords
polypeptide
protein
formula
mature
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP63507739A
Other languages
English (en)
Japanese (ja)
Inventor
フイッシャー，リチャード　エイ
ギルバート，ウォルター
サトー，ビッキー　エル
フレイベル　リチャード　エイ
マラガノア，ジョン　エム
リュー，テリーザ　アール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of JPH02501192A publication Critical patent/JPH02501192A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
JP63507739A 1987-09-04 1988-09-01 可溶性ｔ４蛋白を製造するためのｄｎａ配列、組換ｄｎａ分子および方法 Pending JPH02501192A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9432287A 1987-09-04 1987-09-04
US094,322 1987-09-04
US14164988A 1988-01-07 1988-01-07
US141,649 1988-01-07

Publications (1)

Publication Number Publication Date
JPH02501192A true JPH02501192A (ja) 1990-04-26

Family

ID=26788733

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63507739A Pending JPH02501192A (ja) 1987-09-04 1988-09-01 可溶性ｔ４蛋白を製造するためのｄｎａ配列、組換ｄｎａ分子および方法

Country Status (12)

Country Link
EP (1) EP0347435A4 (pt)
JP (1) JPH02501192A (pt)
KR (1) KR890701605A (pt)
DK (1) DK216589A (pt)
ES (1) ES2013346A6 (pt)
GR (1) GR1000489B (pt)
IL (1) IL87647A0 (pt)
NO (1) NO891818L (pt)
NZ (1) NZ226040A (pt)
OA (1) OA09625A (pt)
PT (1) PT88425B (pt)
WO (1) WO1989001940A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134874B2 (ja) 1986-08-21 2001-02-13 ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク Ｔ細胞表面タンパク質ｔ４をコードするｄｎａ並びにｔ４フラグメントのａｉｄｓ治療への使用
US5958678A (en) * 1986-08-21 1999-09-28 The Trustees Of Columbia University In The City Of New York DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS
ZA887365B (en) * 1987-10-02 1990-05-30 Genentech Inc Adheson variants
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6004781A (en) * 1988-01-22 1999-12-21 The General Hospital Corporation Nucleic acid encoding Ig-CD4 fusion proteins
PT89484B (pt) * 1988-01-22 1994-03-31 Gen Hospital Corp Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
AU3006789A (en) * 1988-02-24 1989-08-24 Smithkline Beckman Corporation Expression of hiv binding proteins
EP0346091A3 (en) * 1988-06-10 1990-09-12 Dana Farber Cancer Institute Method of diagnosis for naturally occurring antibodies to cd4
JPH04502011A (ja) * 1988-11-23 1992-04-09 ジェネンテク，インコーポレイテッド ポリペプチド誘導体
AU5437190A (en) * 1989-04-05 1990-11-05 Upjohn Company, The Soluble cd4 produced in (e. coli)
EP0408372A1 (en) * 1989-07-13 1991-01-16 Smithkline Beecham Corporation Anti-viral therapy
AU648041B2 (en) * 1989-08-23 1994-04-14 General Hospital Corporation, The Non-human primate CD4 polypeptides, fusions thereof, DNA encoding, and uses thereof
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
CA2062758A1 (en) * 1990-05-25 1991-11-26 Richard A. Fisher Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection
DE69126301T2 (de) * 1990-11-27 1998-01-02 Biogen, Inc., Cambridge, Mass. Hiv-induzierte synzytien blockierender anti-cd-4-antikörper
AU1438592A (en) * 1991-02-08 1992-09-07 Progenics Pharmaceuticals, Inc. Cd4-gamma1 and cd4-igg1 chimeras
US7070991B2 (en) 1991-02-08 2006-07-04 Progenics Pharmaceuticals, Inc. Cells expressing a CD4-IgG2 chimeric heterotetramer
DE69233480T2 (de) 1991-02-08 2006-01-05 Progenics Pharmaceuticals, Inc. CD4-gamma2- und CD4-IgG2-Chimären
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
ES2298457T3 (es) * 1994-11-04 2008-05-16 Idexx Laboratories, Inc. Medio para detectar microbios objetivo en una muestra.
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
EP0830368A1 (en) 1995-06-07 1998-03-25 Genta Incorporated Novel carbamate-based cationic lipids
ES2299276T3 (es) 1998-12-31 2008-05-16 Novartis Vaccines And Diagnostics, Inc. Polipeptidos env del vih modificados.
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2000039302A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
CN113209124B (zh) * 2021-02-24 2022-04-15 四川大学 Dna四面体在制备预防和治疗1型糖尿病的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134874B2 (ja) * 1986-08-21 2001-02-13 ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク Ｔ細胞表面タンパク質ｔ４をコードするｄｎａ並びにｔ４フラグメントのａｉｄｓ治療への使用
IL83687A (en) * 1987-08-30 1995-03-30 Yeda Res & Dev Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao

Also Published As

Publication number Publication date
AU626007B2 (en) 1992-07-23
IL87647A0 (en) 1989-02-28
GR880100579A (en) 1989-06-22
EP0347435A1 (en) 1989-12-27
KR890701605A (ko) 1989-12-21
DK216589A (da) 1989-07-04
NO891818D0 (no) 1989-05-02
PT88425A (pt) 1989-07-31
DK216589D0 (da) 1989-05-03
GR1000489B (el) 1992-07-30
OA09625A (en) 1993-04-30
NZ226040A (en) 1992-02-25
EP0347435A4 (en) 1991-11-21
NO891818L (no) 1989-07-03
AU2482988A (en) 1989-03-31
PT88425B (pt) 1992-10-30
WO1989001940A1 (en) 1989-03-09
ES2013346A6 (es) 1990-05-01

Similar Documents

Publication Publication Date Title
JPH02501192A (ja) 可溶性ｔ４蛋白を製造するためのｄｎａ配列、組換ｄｎａ分子および方法
Panté et al. Interactions and three-dimensional localization of a group of nuclear pore complex proteins.
AU682206B2 (en) Intracellular immunization
JPH05505112A (ja) Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
KR100376544B1 (ko) 티(t)세포조절물질및방법
US6818748B2 (en) Cloning, expression, sequencing, and functional enhancement of monoclonal ScFv antibody against Venezuelan equine encephalitis virus (VEE)
DK172110B1 (da) Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner
DE69938062T2 (de) Modifizierte hiv env polypeptide
JPH02501113A (ja) リンパ球機能関連抗原―３（ｌｆａ―３）を製造するためのｄｎａ配列、組換ｄｎａ分子及び方法
JPS61501627A (ja) ヒトエリスロポエチンをコードするｄｎａ
CA2173138A1 (en) Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
US7825085B2 (en) Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells
JPH03504234A (ja) 可溶性ヒトｃｄ４断片及びその使用
AU632683B2 (en) Peptides stimulating cytotoxic t cells immune to hiv rt
US5935579A (en) AIDS therapy and vaccine
EP0414178B1 (en) Non-human primate CD4 polypeptides and human CD4 molecules capable of being glycosylated
KR100375260B1 (ko) 글루카곤수용체
AU765218B2 (en) A novel chimeric protein for prevention and treatment of HIV infection
JPH08149981A (ja) Ｔ細胞α鎖による抗原特異的免疫制御の方法
JPH05501503A (ja) 多量体ゲルゾリン融合構築物
DE69839242T2 (de) Rrekombinante proteine eines pakistani-stammes von hepatitis-e-virus, ihre verwendung in diagnotischen verfahren und als impfstoff
Mitchell et al. Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV
CN112159470B (zh) 一种抗wnv感染的结合分子
JPH05502166A (ja) Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の治療および予防のための免疫治療用組成物
AU626007C (en) DNA sequences, recombinant DNA molecules and processes for producing soluble T4 proteins